arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CORCEPT THERAPEUTICS INC

CORT
$71.62 ▼ -7.68 (-9.68%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
33 Metrics
Peer-ranked Benchmarks
Price Chart
74
Health
Good
Bullish
auto_awesome

Analytical Summary

CORCEPT THERAPEUTICS INC shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $7.4B
Dividend Yield —
Revenue Growth 12.8% ↘
Op. Margin 5.9% ↘
ROIC 10.4% ↘
FCF / Share $1.37 ↘
Trailing P/E 75.4x
Price / Book 11.7x
FCF Yield 1.9%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$761.41M
↑ +12.8% —
Net Income Profit after all expenses
$99.65M
↓ -29.4% —
Operating Margin Operating profit as % of sales
5.9%
↓ -71.0% 45th
FCF / Share Free cash flow per share
$1.37
↓ -28.1% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
65
Returns ↓
81
Cash Quality →
79

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 27 years · 78 quarters